StockData
Adlai Nortye Group Ltd. logo

Adlai Nortye Group Ltd. (ANL) company profile

ANLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 10, 2026Score 0/30
$9.48−0.55 (-5.48%)

Close on Nov 17, 2026Market cap $379.20MP/E –Yield –

About Adlai Nortye

Pharmaceutical Preparations, SIC 2834

Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company that focuses on the discovery and development of innovative drug candidates. The company engages in preclinical research and clinical trials to evaluate therapeutic treatments for targeted diseases. Its operations encompass experimental pharmaceutical therapies designed to address conditions regulated by health agencies such as the United States Food and Drug Administration and the National Medical Products Administration. Its prospective end users are patients suffering from targeted illnesses.

The company maintains its principal executive offices in Grand Cayman, Cayman Islands, with approved plans to redomicile to Singapore. Daily operations are primarily conducted through operating subsidiaries in the United States and mainland China, supported by affiliated entities in Hong Kong, Singapore, and Switzerland. The organization maintains a corporate contact office in North Brunswick, New Jersey, while its Chinese operations include entities in Hangzhou and Shanghai.

Summary of the business section of Adlai Nortye's latest annual report, written by StockData.

Company profile

Company

Legal name
Adlai Nortye Group Ltd.
Headquarters
Singapore, Singapore
Address
77 Robinson Road, #20-01, Robinson 77 068896
Phone
(848) 230-7430
Industry
Pharmaceutical Preparations
Incorporated in
U0
Fiscal year ends
December 31
Auditor
BDO China Shu Lun Pan Certified Public Accountants LLP, Shanghai, The Peoples Republic of China

Stock & identifiers

Ticker
ANL
Exchange
Nasdaq
IPO date
Sep 29, 2023
Shares outstanding
120M, Dec 31, 2025
Filer category
Non-accelerated filer<br>Emerging growth company
SEC CIK
1944552
CUSIP
00704R109
ISIN
US00704R1095
FIGI
BBG01HP11SV4
Share class FIGI
BBG01HP11TP9
LEI
54930009TDXE4YQVKU60
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Yang LuCEO, Director17,089,990
Xiaofeng YeCFO147,788
Archie TsePresident, Head of R&D50,000
Kaiyang TangPresident,Adlai Nortye USA INC–
Ping JiDirector121,453
Lars Erik BirgersonDirector166,668
Roger SawhneyDirector9,838
Alan Ming Lun TseDirector–

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Sep 29, 2023
Securities offered
2,500,000
Exchange
Nasdaq
Lock-up ends (est.)
Mar 27, 2024

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

DateEventDetails
Aug 19, 2026Name changeName changed from Adlai Nortye Ltd. to Adlai Nortye Group Ltd.
Sep 29, 2023IPOInitial public offering priced (424B4 prospectus)
Aug 18, 2023ListingRegistration of securities on an exchange (Form 8-A)
Aug 7, 2023ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?